nodes	percent_of_prediction	percent_of_DWPC	metapath
Topotecan—TOP1—systemic scleroderma	0.63	1	CbGaD
Topotecan—ABCG2—Leflunomide—systemic scleroderma	0.0788	0.307	CbGbCtD
Topotecan—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0487	0.19	CbGbCtD
Topotecan—ABCB1—Lisinopril—systemic scleroderma	0.0298	0.116	CbGbCtD
Topotecan—ABCB1—Captopril—systemic scleroderma	0.0223	0.0869	CbGbCtD
Topotecan—ABCG2—Methotrexate—systemic scleroderma	0.0195	0.0761	CbGbCtD
Topotecan—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0176	0.0684	CbGbCtD
Topotecan—ABCB1—Prednisone—systemic scleroderma	0.014	0.0547	CbGbCtD
Topotecan—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0105	0.041	CbGbCtD
Topotecan—CYP3A4—Prednisone—systemic scleroderma	0.00841	0.0328	CbGbCtD
Topotecan—ABCB1—Methotrexate—systemic scleroderma	0.00704	0.0274	CbGbCtD
Topotecan—Irinotecan—TOP1—systemic scleroderma	0.00487	1	CrCbGaD
Topotecan—Chest pain—Lisinopril—systemic scleroderma	0.000137	0.00126	CcSEcCtD
Topotecan—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000137	0.00126	CcSEcCtD
Topotecan—Dyspnoea—Leflunomide—systemic scleroderma	0.000137	0.00126	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000136	0.00125	CcSEcCtD
Topotecan—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000136	0.00125	CcSEcCtD
Topotecan—Discomfort—Lisinopril—systemic scleroderma	0.000136	0.00125	CcSEcCtD
Topotecan—Lethargy—Methotrexate—systemic scleroderma	0.000136	0.00125	CcSEcCtD
Topotecan—Dyspepsia—Leflunomide—systemic scleroderma	0.000135	0.00124	CcSEcCtD
Topotecan—Vomiting—Mometasone—systemic scleroderma	0.000135	0.00124	CcSEcCtD
Topotecan—Feeling abnormal—Azathioprine—systemic scleroderma	0.000134	0.00123	CcSEcCtD
Topotecan—Rash—Mometasone—systemic scleroderma	0.000134	0.00123	CcSEcCtD
Topotecan—Asthenia—Captopril—systemic scleroderma	0.000133	0.00123	CcSEcCtD
Topotecan—Dermatitis—Mometasone—systemic scleroderma	0.000133	0.00123	CcSEcCtD
Topotecan—Decreased appetite—Leflunomide—systemic scleroderma	0.000133	0.00122	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000133	0.00122	CcSEcCtD
Topotecan—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000133	0.00122	CcSEcCtD
Topotecan—Headache—Mometasone—systemic scleroderma	0.000133	0.00122	CcSEcCtD
Topotecan—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000132	0.00122	CcSEcCtD
Topotecan—Fatigue—Leflunomide—systemic scleroderma	0.000132	0.00121	CcSEcCtD
Topotecan—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000132	0.00121	CcSEcCtD
Topotecan—Pruritus—Captopril—systemic scleroderma	0.000132	0.00121	CcSEcCtD
Topotecan—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000131	0.00121	CcSEcCtD
Topotecan—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000131	0.00121	CcSEcCtD
Topotecan—Pain—Leflunomide—systemic scleroderma	0.000131	0.0012	CcSEcCtD
Topotecan—Constipation—Leflunomide—systemic scleroderma	0.000131	0.0012	CcSEcCtD
Topotecan—Infection—Lisinopril—systemic scleroderma	0.000131	0.0012	CcSEcCtD
Topotecan—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000131	0.0012	CcSEcCtD
Topotecan—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00013	0.0012	CcSEcCtD
Topotecan—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000129	0.00119	CcSEcCtD
Topotecan—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000129	0.00119	CcSEcCtD
Topotecan—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000129	0.00118	CcSEcCtD
Topotecan—Neutropenia—Prednisone—systemic scleroderma	0.000129	0.00118	CcSEcCtD
Topotecan—Abdominal pain—Azathioprine—systemic scleroderma	0.000128	0.00118	CcSEcCtD
Topotecan—Body temperature increased—Azathioprine—systemic scleroderma	0.000128	0.00118	CcSEcCtD
Topotecan—Skin disorder—Lisinopril—systemic scleroderma	0.000128	0.00118	CcSEcCtD
Topotecan—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000128	0.00117	CcSEcCtD
Topotecan—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000127	0.00117	CcSEcCtD
Topotecan—Diarrhoea—Captopril—systemic scleroderma	0.000127	0.00117	CcSEcCtD
Topotecan—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000127	0.00117	CcSEcCtD
Topotecan—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000127	0.00116	CcSEcCtD
Topotecan—Feeling abnormal—Leflunomide—systemic scleroderma	0.000126	0.00116	CcSEcCtD
Topotecan—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000126	0.00116	CcSEcCtD
Topotecan—Fatigue—Mycophenolic acid—systemic scleroderma	0.000126	0.00116	CcSEcCtD
Topotecan—Nausea—Mometasone—systemic scleroderma	0.000126	0.00116	CcSEcCtD
Topotecan—Anorexia—Lisinopril—systemic scleroderma	0.000126	0.00115	CcSEcCtD
Topotecan—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000125	0.00115	CcSEcCtD
Topotecan—Weight increased—Prednisone—systemic scleroderma	0.000125	0.00115	CcSEcCtD
Topotecan—Constipation—Mycophenolic acid—systemic scleroderma	0.000125	0.00115	CcSEcCtD
Topotecan—Pain—Mycophenolic acid—systemic scleroderma	0.000125	0.00115	CcSEcCtD
Topotecan—Cough—Mycophenolate mofetil—systemic scleroderma	0.000123	0.00113	CcSEcCtD
Topotecan—Dizziness—Captopril—systemic scleroderma	0.000123	0.00113	CcSEcCtD
Topotecan—Urticaria—Leflunomide—systemic scleroderma	0.000122	0.00112	CcSEcCtD
Topotecan—Abdominal pain—Leflunomide—systemic scleroderma	0.000121	0.00111	CcSEcCtD
Topotecan—Body temperature increased—Leflunomide—systemic scleroderma	0.000121	0.00111	CcSEcCtD
Topotecan—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000121	0.00111	CcSEcCtD
Topotecan—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.00012	0.00111	CcSEcCtD
Topotecan—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00012	0.00111	CcSEcCtD
Topotecan—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.00012	0.00111	CcSEcCtD
Topotecan—Neuropathy peripheral—Prednisone—systemic scleroderma	0.00012	0.0011	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00012	0.0011	CcSEcCtD
Topotecan—Hypersensitivity—Azathioprine—systemic scleroderma	0.00012	0.0011	CcSEcCtD
Topotecan—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00012	0.0011	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00012	0.0011	CcSEcCtD
Topotecan—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000119	0.00109	CcSEcCtD
Topotecan—Paraesthesia—Lisinopril—systemic scleroderma	0.000118	0.00109	CcSEcCtD
Topotecan—Vomiting—Captopril—systemic scleroderma	0.000118	0.00109	CcSEcCtD
Topotecan—Dyspnoea—Lisinopril—systemic scleroderma	0.000117	0.00108	CcSEcCtD
Topotecan—Rash—Captopril—systemic scleroderma	0.000117	0.00108	CcSEcCtD
Topotecan—Dermatitis—Captopril—systemic scleroderma	0.000117	0.00108	CcSEcCtD
Topotecan—Headache—Captopril—systemic scleroderma	0.000117	0.00107	CcSEcCtD
Topotecan—Dyspepsia—Lisinopril—systemic scleroderma	0.000116	0.00107	CcSEcCtD
Topotecan—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000116	0.00106	CcSEcCtD
Topotecan—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000116	0.00106	CcSEcCtD
Topotecan—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000115	0.00106	CcSEcCtD
Topotecan—Infection—Mycophenolate mofetil—systemic scleroderma	0.000115	0.00105	CcSEcCtD
Topotecan—Decreased appetite—Lisinopril—systemic scleroderma	0.000115	0.00105	CcSEcCtD
Topotecan—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000114	0.00104	CcSEcCtD
Topotecan—Fatigue—Lisinopril—systemic scleroderma	0.000114	0.00104	CcSEcCtD
Topotecan—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000113	0.00104	CcSEcCtD
Topotecan—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000113	0.00104	CcSEcCtD
Topotecan—Hypersensitivity—Leflunomide—systemic scleroderma	0.000113	0.00104	CcSEcCtD
Topotecan—Pain—Lisinopril—systemic scleroderma	0.000113	0.00104	CcSEcCtD
Topotecan—Constipation—Lisinopril—systemic scleroderma	0.000113	0.00104	CcSEcCtD
Topotecan—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000112	0.00103	CcSEcCtD
Topotecan—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000112	0.00103	CcSEcCtD
Topotecan—Diarrhoea—Azathioprine—systemic scleroderma	0.000111	0.00102	CcSEcCtD
Topotecan—Haemoglobin—Prednisone—systemic scleroderma	0.000111	0.00102	CcSEcCtD
Topotecan—Nausea—Captopril—systemic scleroderma	0.000111	0.00102	CcSEcCtD
Topotecan—Haemorrhage—Prednisone—systemic scleroderma	0.00011	0.00101	CcSEcCtD
Topotecan—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00011	0.00101	CcSEcCtD
Topotecan—Asthenia—Leflunomide—systemic scleroderma	0.00011	0.00101	CcSEcCtD
Topotecan—Pancytopenia—Methotrexate—systemic scleroderma	0.000109	0.001	CcSEcCtD
Topotecan—Feeling abnormal—Lisinopril—systemic scleroderma	0.000109	0.000997	CcSEcCtD
Topotecan—Pruritus—Leflunomide—systemic scleroderma	0.000108	0.000997	CcSEcCtD
Topotecan—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000108	0.00099	CcSEcCtD
Topotecan—Neutropenia—Methotrexate—systemic scleroderma	0.000108	0.000988	CcSEcCtD
Topotecan—Dizziness—Azathioprine—systemic scleroderma	0.000107	0.000986	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000966	CcSEcCtD
Topotecan—Asthenia—Mycophenolic acid—systemic scleroderma	0.000105	0.000964	CcSEcCtD
Topotecan—Diarrhoea—Leflunomide—systemic scleroderma	0.000105	0.000964	CcSEcCtD
Topotecan—Urticaria—Lisinopril—systemic scleroderma	0.000105	0.000962	CcSEcCtD
Topotecan—Abdominal pain—Lisinopril—systemic scleroderma	0.000104	0.000957	CcSEcCtD
Topotecan—Body temperature increased—Lisinopril—systemic scleroderma	0.000104	0.000957	CcSEcCtD
Topotecan—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000952	CcSEcCtD
Topotecan—Pruritus—Mycophenolic acid—systemic scleroderma	0.000103	0.000951	CcSEcCtD
Topotecan—Vomiting—Azathioprine—systemic scleroderma	0.000103	0.000948	CcSEcCtD
Topotecan—Pneumonia—Methotrexate—systemic scleroderma	0.000103	0.000947	CcSEcCtD
Topotecan—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000945	CcSEcCtD
Topotecan—Infestation—Methotrexate—systemic scleroderma	0.000103	0.000942	CcSEcCtD
Topotecan—Infestation NOS—Methotrexate—systemic scleroderma	0.000103	0.000942	CcSEcCtD
Topotecan—Rash—Azathioprine—systemic scleroderma	0.000102	0.00094	CcSEcCtD
Topotecan—Dermatitis—Azathioprine—systemic scleroderma	0.000102	0.00094	CcSEcCtD
Topotecan—Headache—Azathioprine—systemic scleroderma	0.000102	0.000934	CcSEcCtD
Topotecan—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000933	CcSEcCtD
Topotecan—Dizziness—Leflunomide—systemic scleroderma	0.000101	0.000931	CcSEcCtD
Topotecan—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.0001	0.000922	CcSEcCtD
Topotecan—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.0001	0.000919	CcSEcCtD
Topotecan—Stomatitis—Methotrexate—systemic scleroderma	9.99e-05	0.000918	CcSEcCtD
Topotecan—Angiopathy—Prednisone—systemic scleroderma	9.99e-05	0.000918	CcSEcCtD
Topotecan—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	9.97e-05	0.000916	CcSEcCtD
Topotecan—Immune system disorder—Prednisone—systemic scleroderma	9.95e-05	0.000914	CcSEcCtD
Topotecan—Pain—Mycophenolate mofetil—systemic scleroderma	9.87e-05	0.000907	CcSEcCtD
Topotecan—Constipation—Mycophenolate mofetil—systemic scleroderma	9.87e-05	0.000907	CcSEcCtD
Topotecan—Sweating—Methotrexate—systemic scleroderma	9.83e-05	0.000903	CcSEcCtD
Topotecan—Vomiting—Leflunomide—systemic scleroderma	9.75e-05	0.000896	CcSEcCtD
Topotecan—Alopecia—Prednisone—systemic scleroderma	9.73e-05	0.000894	CcSEcCtD
Topotecan—Hypersensitivity—Lisinopril—systemic scleroderma	9.71e-05	0.000892	CcSEcCtD
Topotecan—Hepatobiliary disease—Methotrexate—systemic scleroderma	9.7e-05	0.000891	CcSEcCtD
Topotecan—Dizziness—Mycophenolic acid—systemic scleroderma	9.67e-05	0.000889	CcSEcCtD
Topotecan—Epistaxis—Methotrexate—systemic scleroderma	9.67e-05	0.000888	CcSEcCtD
Topotecan—Rash—Leflunomide—systemic scleroderma	9.67e-05	0.000888	CcSEcCtD
Topotecan—Dermatitis—Leflunomide—systemic scleroderma	9.66e-05	0.000887	CcSEcCtD
Topotecan—Nausea—Azathioprine—systemic scleroderma	9.64e-05	0.000886	CcSEcCtD
Topotecan—Headache—Leflunomide—systemic scleroderma	9.61e-05	0.000882	CcSEcCtD
Topotecan—Malnutrition—Prednisone—systemic scleroderma	9.59e-05	0.000881	CcSEcCtD
Topotecan—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	9.51e-05	0.000874	CcSEcCtD
Topotecan—Asthenia—Lisinopril—systemic scleroderma	9.45e-05	0.000868	CcSEcCtD
Topotecan—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	9.44e-05	0.000867	CcSEcCtD
Topotecan—Pruritus—Lisinopril—systemic scleroderma	9.32e-05	0.000856	CcSEcCtD
Topotecan—Vomiting—Mycophenolic acid—systemic scleroderma	9.3e-05	0.000854	CcSEcCtD
Topotecan—Haemoglobin—Methotrexate—systemic scleroderma	9.25e-05	0.00085	CcSEcCtD
Topotecan—Rash—Mycophenolic acid—systemic scleroderma	9.22e-05	0.000847	CcSEcCtD
Topotecan—Dermatitis—Mycophenolic acid—systemic scleroderma	9.21e-05	0.000846	CcSEcCtD
Topotecan—Haemorrhage—Methotrexate—systemic scleroderma	9.2e-05	0.000846	CcSEcCtD
Topotecan—Urticaria—Mycophenolate mofetil—systemic scleroderma	9.17e-05	0.000842	CcSEcCtD
Topotecan—Headache—Mycophenolic acid—systemic scleroderma	9.16e-05	0.000842	CcSEcCtD
Topotecan—Pharyngitis—Methotrexate—systemic scleroderma	9.14e-05	0.000839	CcSEcCtD
Topotecan—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	9.13e-05	0.000838	CcSEcCtD
Topotecan—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	9.13e-05	0.000838	CcSEcCtD
Topotecan—Nausea—Leflunomide—systemic scleroderma	9.11e-05	0.000837	CcSEcCtD
Topotecan—Diarrhoea—Lisinopril—systemic scleroderma	9.01e-05	0.000828	CcSEcCtD
Topotecan—Ill-defined disorder—Prednisone—systemic scleroderma	8.9e-05	0.000817	CcSEcCtD
Topotecan—Anaemia—Prednisone—systemic scleroderma	8.86e-05	0.000814	CcSEcCtD
Topotecan—Angioedema—Prednisone—systemic scleroderma	8.76e-05	0.000805	CcSEcCtD
Topotecan—Dizziness—Lisinopril—systemic scleroderma	8.71e-05	0.0008	CcSEcCtD
Topotecan—Nausea—Mycophenolic acid—systemic scleroderma	8.69e-05	0.000798	CcSEcCtD
Topotecan—Malaise—Prednisone—systemic scleroderma	8.65e-05	0.000794	CcSEcCtD
Topotecan—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	8.5e-05	0.000781	CcSEcCtD
Topotecan—Vomiting—Lisinopril—systemic scleroderma	8.38e-05	0.00077	CcSEcCtD
Topotecan—Angiopathy—Methotrexate—systemic scleroderma	8.35e-05	0.000767	CcSEcCtD
Topotecan—Immune system disorder—Methotrexate—systemic scleroderma	8.31e-05	0.000764	CcSEcCtD
Topotecan—Rash—Lisinopril—systemic scleroderma	8.31e-05	0.000763	CcSEcCtD
Topotecan—Dermatitis—Lisinopril—systemic scleroderma	8.3e-05	0.000762	CcSEcCtD
Topotecan—Mediastinal disorder—Methotrexate—systemic scleroderma	8.3e-05	0.000762	CcSEcCtD
Topotecan—Asthenia—Mycophenolate mofetil—systemic scleroderma	8.28e-05	0.000761	CcSEcCtD
Topotecan—Chills—Methotrexate—systemic scleroderma	8.26e-05	0.000759	CcSEcCtD
Topotecan—Headache—Lisinopril—systemic scleroderma	8.25e-05	0.000758	CcSEcCtD
Topotecan—Pruritus—Mycophenolate mofetil—systemic scleroderma	8.17e-05	0.00075	CcSEcCtD
Topotecan—Myalgia—Prednisone—systemic scleroderma	8.16e-05	0.00075	CcSEcCtD
Topotecan—Arthralgia—Prednisone—systemic scleroderma	8.16e-05	0.00075	CcSEcCtD
Topotecan—Alopecia—Methotrexate—systemic scleroderma	8.13e-05	0.000747	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	8.11e-05	0.000745	CcSEcCtD
Topotecan—Discomfort—Prednisone—systemic scleroderma	8.06e-05	0.000741	CcSEcCtD
Topotecan—Malnutrition—Methotrexate—systemic scleroderma	8.01e-05	0.000736	CcSEcCtD
Topotecan—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	7.9e-05	0.000726	CcSEcCtD
Topotecan—Nausea—Lisinopril—systemic scleroderma	7.83e-05	0.000719	CcSEcCtD
Topotecan—Anaphylactic shock—Prednisone—systemic scleroderma	7.82e-05	0.000719	CcSEcCtD
Topotecan—Infection—Prednisone—systemic scleroderma	7.77e-05	0.000714	CcSEcCtD
Topotecan—Back pain—Methotrexate—systemic scleroderma	7.75e-05	0.000712	CcSEcCtD
Topotecan—Nervous system disorder—Prednisone—systemic scleroderma	7.67e-05	0.000705	CcSEcCtD
Topotecan—Dizziness—Mycophenolate mofetil—systemic scleroderma	7.63e-05	0.000701	CcSEcCtD
Topotecan—Skin disorder—Prednisone—systemic scleroderma	7.6e-05	0.000698	CcSEcCtD
Topotecan—Hyperhidrosis—Prednisone—systemic scleroderma	7.56e-05	0.000695	CcSEcCtD
Topotecan—Anorexia—Prednisone—systemic scleroderma	7.46e-05	0.000685	CcSEcCtD
Topotecan—Ill-defined disorder—Methotrexate—systemic scleroderma	7.43e-05	0.000683	CcSEcCtD
Topotecan—Anaemia—Methotrexate—systemic scleroderma	7.41e-05	0.00068	CcSEcCtD
Topotecan—Vomiting—Mycophenolate mofetil—systemic scleroderma	7.34e-05	0.000674	CcSEcCtD
Topotecan—Rash—Mycophenolate mofetil—systemic scleroderma	7.28e-05	0.000669	CcSEcCtD
Topotecan—Dermatitis—Mycophenolate mofetil—systemic scleroderma	7.27e-05	0.000668	CcSEcCtD
Topotecan—Headache—Mycophenolate mofetil—systemic scleroderma	7.23e-05	0.000664	CcSEcCtD
Topotecan—Malaise—Methotrexate—systemic scleroderma	7.23e-05	0.000664	CcSEcCtD
Topotecan—Leukopenia—Methotrexate—systemic scleroderma	7.17e-05	0.000659	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Prednisone—systemic scleroderma	7.13e-05	0.000655	CcSEcCtD
Topotecan—Paraesthesia—Prednisone—systemic scleroderma	7.03e-05	0.000645	CcSEcCtD
Topotecan—Cough—Methotrexate—systemic scleroderma	6.99e-05	0.000642	CcSEcCtD
Topotecan—Dyspepsia—Prednisone—systemic scleroderma	6.89e-05	0.000633	CcSEcCtD
Topotecan—Nausea—Mycophenolate mofetil—systemic scleroderma	6.86e-05	0.00063	CcSEcCtD
Topotecan—Arthralgia—Methotrexate—systemic scleroderma	6.82e-05	0.000627	CcSEcCtD
Topotecan—Myalgia—Methotrexate—systemic scleroderma	6.82e-05	0.000627	CcSEcCtD
Topotecan—Chest pain—Methotrexate—systemic scleroderma	6.82e-05	0.000627	CcSEcCtD
Topotecan—Decreased appetite—Prednisone—systemic scleroderma	6.8e-05	0.000625	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	6.77e-05	0.000622	CcSEcCtD
Topotecan—Fatigue—Prednisone—systemic scleroderma	6.75e-05	0.00062	CcSEcCtD
Topotecan—Discomfort—Methotrexate—systemic scleroderma	6.74e-05	0.000619	CcSEcCtD
Topotecan—Constipation—Prednisone—systemic scleroderma	6.69e-05	0.000615	CcSEcCtD
Topotecan—Anaphylactic shock—Methotrexate—systemic scleroderma	6.54e-05	0.000601	CcSEcCtD
Topotecan—Infection—Methotrexate—systemic scleroderma	6.5e-05	0.000597	CcSEcCtD
Topotecan—Feeling abnormal—Prednisone—systemic scleroderma	6.45e-05	0.000592	CcSEcCtD
Topotecan—Nervous system disorder—Methotrexate—systemic scleroderma	6.41e-05	0.000589	CcSEcCtD
Topotecan—Thrombocytopenia—Methotrexate—systemic scleroderma	6.4e-05	0.000588	CcSEcCtD
Topotecan—Gastrointestinal pain—Prednisone—systemic scleroderma	6.4e-05	0.000588	CcSEcCtD
Topotecan—Skin disorder—Methotrexate—systemic scleroderma	6.35e-05	0.000584	CcSEcCtD
Topotecan—Hyperhidrosis—Methotrexate—systemic scleroderma	6.32e-05	0.000581	CcSEcCtD
Topotecan—Anorexia—Methotrexate—systemic scleroderma	6.23e-05	0.000573	CcSEcCtD
Topotecan—Urticaria—Prednisone—systemic scleroderma	6.22e-05	0.000571	CcSEcCtD
Topotecan—Abdominal pain—Prednisone—systemic scleroderma	6.19e-05	0.000568	CcSEcCtD
Topotecan—Body temperature increased—Prednisone—systemic scleroderma	6.19e-05	0.000568	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	5.96e-05	0.000547	CcSEcCtD
Topotecan—Paraesthesia—Methotrexate—systemic scleroderma	5.87e-05	0.000539	CcSEcCtD
Topotecan—Dyspnoea—Methotrexate—systemic scleroderma	5.83e-05	0.000536	CcSEcCtD
Topotecan—Hypersensitivity—Prednisone—systemic scleroderma	5.76e-05	0.00053	CcSEcCtD
Topotecan—Dyspepsia—Methotrexate—systemic scleroderma	5.76e-05	0.000529	CcSEcCtD
Topotecan—Decreased appetite—Methotrexate—systemic scleroderma	5.68e-05	0.000522	CcSEcCtD
Topotecan—Gastrointestinal disorder—Methotrexate—systemic scleroderma	5.65e-05	0.000519	CcSEcCtD
Topotecan—Fatigue—Methotrexate—systemic scleroderma	5.64e-05	0.000518	CcSEcCtD
Topotecan—Asthenia—Prednisone—systemic scleroderma	5.61e-05	0.000516	CcSEcCtD
Topotecan—Pain—Methotrexate—systemic scleroderma	5.59e-05	0.000514	CcSEcCtD
Topotecan—Pruritus—Prednisone—systemic scleroderma	5.54e-05	0.000509	CcSEcCtD
Topotecan—Feeling abnormal—Methotrexate—systemic scleroderma	5.39e-05	0.000495	CcSEcCtD
Topotecan—Diarrhoea—Prednisone—systemic scleroderma	5.35e-05	0.000492	CcSEcCtD
Topotecan—Gastrointestinal pain—Methotrexate—systemic scleroderma	5.35e-05	0.000491	CcSEcCtD
Topotecan—Urticaria—Methotrexate—systemic scleroderma	5.19e-05	0.000477	CcSEcCtD
Topotecan—Dizziness—Prednisone—systemic scleroderma	5.17e-05	0.000475	CcSEcCtD
Topotecan—Body temperature increased—Methotrexate—systemic scleroderma	5.17e-05	0.000475	CcSEcCtD
Topotecan—Abdominal pain—Methotrexate—systemic scleroderma	5.17e-05	0.000475	CcSEcCtD
Topotecan—Vomiting—Prednisone—systemic scleroderma	4.97e-05	0.000457	CcSEcCtD
Topotecan—Rash—Prednisone—systemic scleroderma	4.93e-05	0.000453	CcSEcCtD
Topotecan—Dermatitis—Prednisone—systemic scleroderma	4.93e-05	0.000453	CcSEcCtD
Topotecan—Headache—Prednisone—systemic scleroderma	4.9e-05	0.00045	CcSEcCtD
Topotecan—Hypersensitivity—Methotrexate—systemic scleroderma	4.82e-05	0.000443	CcSEcCtD
Topotecan—Asthenia—Methotrexate—systemic scleroderma	4.69e-05	0.000431	CcSEcCtD
Topotecan—Nausea—Prednisone—systemic scleroderma	4.65e-05	0.000427	CcSEcCtD
Topotecan—Pruritus—Methotrexate—systemic scleroderma	4.63e-05	0.000425	CcSEcCtD
Topotecan—Diarrhoea—Methotrexate—systemic scleroderma	4.47e-05	0.000411	CcSEcCtD
Topotecan—Dizziness—Methotrexate—systemic scleroderma	4.32e-05	0.000397	CcSEcCtD
Topotecan—Vomiting—Methotrexate—systemic scleroderma	4.16e-05	0.000382	CcSEcCtD
Topotecan—Rash—Methotrexate—systemic scleroderma	4.12e-05	0.000379	CcSEcCtD
Topotecan—Dermatitis—Methotrexate—systemic scleroderma	4.12e-05	0.000378	CcSEcCtD
Topotecan—Headache—Methotrexate—systemic scleroderma	4.1e-05	0.000376	CcSEcCtD
Topotecan—Nausea—Methotrexate—systemic scleroderma	3.88e-05	0.000357	CcSEcCtD
